Ticker
    NVO

    Price
    195.40
    Stock movement up
    +0.02 (0.01%)
    Company name
    Novo Nordisk A/S
    Exchange
    (NYSE
    ,
    Currency
    USD
    )
    Sector
    Healthcare >
    Biotechnology
    Market cap
    439.62B
    Ent value
    584.73B
    Price/Sales
    2.48
    Price/Book
    5.27
    Div yield
    0.90%
    Div growth
    10.20%
    Growth years
    -
    FCF payout
    102.95%
    Trailing P/E
    7.92
    Forward P/E
    37.36
    PEG
    5.74
    EPS growth
    5.90%
    1 year return
    86.40%
    3 year return
    44.26%
    5 year return
    31.98%
    10 year return
    19.33%
    Last updated: 2023-09-08
    Novo Nordisk taps Ypsomed for long-term supply of autoinjectors
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    September 20, 2023

    iO Charts is a Seeking Alpha partner

    Novo Nordisk: What The Stock Split Means For Traders And Investors
    Novo Nordisk announced a share split, aiming to enhance share price appreciation and facilitate options trading for investors. Learn more on NONOF stock here.
    September 20, 2023

    iO Charts is a Seeking Alpha partner

    DIVIDENDS

    Dividend yield - 5y

    Dividend yield data
    Dividend per share1.77
    Dividend yield0.90%
    Payout frequencySemi-annual
    Maximum yield3.74%
    Average yield1.87%
    Minimum yield0.62%
    Discount to avg yield-106.24%
    Upside potential-51.51%
    Yield as % of max yield24.18%

    Yield distribution (inverse percentile) - 5y

    Yield distribution data
    Dividend yield0.90%
    Current yield distribution86.67%
    Yield at 100% (Min)0.62%
    Yield at 90%0.83%
    Yield at 80%1.11%
    Yield at 50% (Median)1.57%
    Yield at 20%2.75%
    Yield at 10%3.13%
    Yield at 0% (Max)3.74%

    Dividend per share

    Dividend per share data
    Years of growth-
    CCC status-
    Dividend per share1.77
    Payout frequencySemi-annual
    Ex-div date18 Aug 2023
    EPS (TTM)24.48
    EPS (1y forward)5.23
    EPS growth (5y)5.90%
    EPS growth (5y forward)1.38%

    Dividend growth

    Please create a free account or log in to access this chart
    Dividend growth data
    NVOS&P500
    DGR MR51.41%8.78%
    DGR TTM13.59%8.57%
    DGR 3 years2.61%4.00%
    DGR 5 years10.20%5.65%
    DGR 10 years13.72%7.37%
    DGR 15 years17.11%5.83%
    Time since last change announced44 days
    EPS growth (5y)5.90%
    EPS growth (5y forward)1.38%

    Payout ratio

    Please create a free account or log in to access this chart
    Payout ratio data
    EPS coverageFCF coverage
    TTM119.40%102.95%
    Average--
    Forward33.79%-
    AD

    VALUATION

    Valuation Ratios

    Valuation Ratios data
    Trailing P/E7.92
    Price to OCF5.57
    Price to FCF6.83
    Price to EBITDA5.74
    EV to EBITDA7.63

    Valuation (Sales/Book Value)

    Valuation (Sales/Book Value) data
    Price to Sales2.48
    Price to Book5.27
    EV to Sales3.30
    Novo Nordisk facility in N.C. flagged for quality control issues - Reuters
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    September 20, 2023

    iO Charts is a Seeking Alpha partner

    Novo Nordisk announces two-for-one stock split
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    September 13, 2023

    iO Charts is a Seeking Alpha partner

    FINANCIALS

    Per share

    Per share data
    Current share count2.25B
    EPS (TTM)24.48
    FCF per share (TTM)28.39

    Income statement

    Income statement data
    Revenue (TTM)176.95B
    Gross profit (TTM)148.51B
    Operating income (TTM)74.81B
    Net income (TTM)55.52B
    EPS (TTM)24.48
    EPS (1y forward)5.23

    Margins

    Margins data
    Gross margin (TTM)83.92%
    Operating margin (TTM)42.28%
    Profit margin (TTM)31.38%

    Balance Sheet

    Please create a free account or log in to access this chart
    Balance Sheet data
    Cash12.65B
    Net receivables57.51B
    Total current assets108.19B
    Goodwill5.09B
    Intangible assets46.32B
    Property, plant and equipment0.00
    Total assets241.26B
    Accounts payable15.59B
    Short/Current long term debt25.78B
    Total current liabilities120.94B
    Total liabilities157.77B
    Shareholder's equity83.49B
    Net tangible assets0.00

    Cash flow

    Please create a free account or log in to access this chart
    Cash flow data
    Operating cash flow (TTM)78.89B
    Capital expenditures (TTM)14.75B
    Free cash flow (TTM)64.39B
    Dividends paid (TTM)66.30B

    Financial returns

    Please create a free account or log in to access this chart
    Financial returns data
    Return on Equity66.51%
    Return on Assets23.01%
    Return on Invested Capital52.52%
    Cash Return on Invested Capital60.91%
    AD

    STOCK INFORMATION

    Stock chart

    Stock price data
    Open194.40
    Daily high196.11
    Daily low193.71
    Daily Volume1.95M
    All-time high195.40
    1y analyst estimate152.49
    Beta0.31
    EPS (TTM)24.48
    Dividend per share1.77
    Ex-div date18 Aug 2023
    Next earnings date2 Nov 2023

    Downside potential

    Downside potential data
    NVOS&P500
    Current price drop from All-time high-0.56%-5.55%
    Highest price drop-51.74%-56.47%
    Date of highest drop5 Aug 20029 Mar 2009
    Avg drop from high-11.14%-11.49%
    Avg time to new high15 days13 days
    Max time to new high1120 days1805 days
    Eli Lilly, Novo to lead $100B weight loss drug market in 2030: JPMorgan
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    September 10, 2023

    iO Charts is a Seeking Alpha partner

    Researchers study weight loss drugs in dementia and addiction
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    September 7, 2023

    iO Charts is a Seeking Alpha partner

    COMPANY DETAILS
    NVO (Novo Nordisk A/S) company logo
    Marketcap
    439.62B
    Marketcap category
    Large-cap
    Description
    Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
    Employees
    54393
    Website
    https://www.novonordisk.com
    Investor relations
    SEC filings
    NVO SEC filings
    CEO
    Lars Fruergaard Joergensen
    Country
    USA
    City
    Novo Alle
    Stock type
    American depositary share
    CCC status
    -
    Dividend Frequency
    Semi-annual
    EVENTS AND PRESENTATIONS
    EventsPresentations
    Novo Nordisk announces limited launch of Wegovy in U.K.
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    September 5, 2023

    iO Charts is a Seeking Alpha partner

    Novo Nordisk briefly dethrones LVMH as EU's most valuable company
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    September 1, 2023

    iO Charts is a Seeking Alpha partner

    UNDERSTAND THE BUSINESS
    COMPANY NEWS
    Seeking AlphaPress releases
    Senators ask Novo Nordisk, Lilly, Sanofi for details on discount insulin programs
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    August 31, 2023
    Study finds Wegovy least cost-effective drug option for teen weight loss
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    August 31, 2023
    Novo Nordisk: Super Focused Pharma Company For The Long Run
    Novo Nordisk is one of the most qualitative big pharma companies globally. Read why I am bullish on NVO stock with the long-term investment horizon here.
    August 31, 2023
    Novo Nordisk: Strong Fundamentals Meet Technical Uptrends
    Novo Nordisk excels in weight loss and diabetes care, showcasing strong financials & a broad product range. Click here to read an analysis on NVO stock now.
    August 30, 2023
    Novo Nordisk scoops up Embark Biotech amid foray into obesity
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    August 30, 2023
    Novo Nordisk chief 'confident' Catalent Wegovy issues will be fixed - report
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    August 25, 2023
    Eli Lilly And Novo Nordisk: Are Weight Loss Drugs A Global Revolution Or Short-Lived Fad?
    Eli Lilly (LLY) and Novo Nordisk's (NVO) current valuations are not sustainable and there exist numerous adverse factors. Learn what are those adverse factors.
    August 24, 2023
    Novo Nordisk said to have added Thermo Fisher for Wegovy production
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    August 23, 2023
    Drugmakers still chasing potentially lucrative NASH market, despite setbacks
    Get the latest news and real-time alerts from Novo Nordisk A/S (NVO) stock at Seeking Alpha.
    August 14, 2023
    Novo Nordisk A/S 2023 Q2 - Results - Earnings Call Presentation
    The following slide deck was published by Novo Nordisk A/S in conjunction with their 2023 Q2 earnings call.
    August 10, 2023
    iO Charts is a Seeking Alpha partnerNext page
    Social
    Menu
    Home
    Portfolio Management
    Company Screener
    Green Investment
    About us
    Contact support
    Language EN | HU | NO | SE | DK | FI | ES | DE | NL | FR | IT | PT | PL | CZ | SK | RO | GR | TR | RU | AF
    Disclaimer
    iO Charts assumes no responsibility or liability for any errors or omissions in the content of this site. The information contained in this site is provided on an “as is” basis with no guarantees of completeness, accuracy, usefulness or timeliness. Please also note, that any action you take upon the information provided on this website is strictly at your own risk. This website is intended to be used and must be used for informational purposes only and you should take independent financial advice from a professional and independently research and verify everything you see on the site.
    © 2023 iO Charts All Rights Reserved